	Application No.	Applicant(s)
•	10/511,506	CAMPBELL ET AL.
Notice of Allowability	Examiner	Art Unit
	Kamal A. Saeed	1626
The MAILING DATE of this communication apper All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHT of the Office or upon petition by the applicant. See 37 CFR 1.313 1. This communication is responsive to 2. The allowed claim(s) is/are 1-7 and 10 now renumbered as 3. Acknowledgment is made of a claim for foreign priority un a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received:	(OR REMAINS) CLOSED in this application of the appropriate communication GHTS. This application is subject to and MPEP 1308. S.1-8. der 35 U.S.C. § 119(a)-(d) or (f). been received. been received in Application No	olication. If not included will be mailed in due course. THIS withdrawal from issue at the initiative
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) ☐ hereto or 2) ☐ to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. 		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5 Notice of Informal B	otent Application (DTO 152)
Notice of References Cited (PTO-092) Notice of Draftperson's Patent Drawing Review (PTO-948)		atent Application (PTO-152)
	6. ⊠ Interview Summary Paper No./Mail Dat	ė
3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/08 — Paper No./Mail Date 11 123/05; to//5/04	8), 7. 🛛 Examiner's Amendr	nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	nt of Reasons for Allowance
of Biological Material	0. \square Other	
	9. ☐ Other	
•		

Application/Control Number: 10/511,506

Art Unit: 1626

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with John C. Todaro on December 05 2005.

The application has been amended as follows:

In claim 1, line 4, delete the term "comprises" and insert --- consists of ----

In claim 10, line 1, delete the term "or prone to"

Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

This invention relates to compounds of Formula

$$\bigcap_{0\geqslant s-N}^{\mathbf{R}^{H}} \bigcirc -\mathbf{c} \equiv \mathbf{c} - \mathbf{x}$$
 as de

in claim 1. The invention also relates to the pharmaceutical use of these compounds. The closest prior art is WO 01/70677 A1 to MERCK SHARP & DOHME LIMITED. WO `70677 teaches

sulfonamide-substituted compounds of Formula

The compounds

described in this application differ from the prior art in that the compounds described in this application have a thiadiazole 1,1-dioxide group. Moreover the compounds of this application have an alkyne group attached directly to the phenyl ring. The prior art also fail to teach or suggest the instant processes of this application.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kamal A Saeed whose telephone number is (571) 272-0705. The examiner can normally be reached on M-T 7:00 AM- 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Joseph K. McKane, can be reached at (571) 272-0699.

Communication via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signiture, may be used by applicant and should be addressed to [joseph mckane@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or public PAIR only. For more information about the

Application/Control Number: 10/511,506

Art Unit: 1626

pair system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private

PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197.

KAMAL A. SAEED, PH.D.

Kamal Saeed, Ph.D.,

Patent Examiner, AU 1626

Page 4